Tissue Regenix Ltd - John Samuel, former CEO of Mölnlycke Health Care Group, appointed Chairman
18 Apr 2008
John Samuel, former CEO of Mölnlycke Health Care Group (MHCG), third in the European advanced wound care market and # 1 European single use-surgical products provider, has joined Tissue Regenix, a University of Leeds spin off company developing revolutionary products in tissue regeneration, as Chairman.
Tissue Regenix, which recently received a £3M investment
package from a syndicate of
investors, is delighted to have the new Chairman on board.
John Fisher, a founder and Director of Tissue
Regenix, commented: "John's experience and knowledge of
the healthcare sector is phenomenal. He has led one of the world's
largest health care groups and delivered outstanding returns for
investors. We are very pleased that he has chosen to join Tissue
Regenix and see this as a real coup for the company.”
John Samuel, Chairman of Tissue Regenix, commented: "I am delighted to be joining Tissue Regenix at this stage of the company’s development. I believe that the company’s technology could offer ground breaking advances in the field of tissue regeneration and look forward to working with the team to deliver on that potential.”
MHCG was sold last year to Investor AB and Morgan Stanley Principal Investments (MSPI) for EUR 2.85 bn.
Notes for Editors
About John Samuel
John Samuel was formerly CEO of the Mölnlycke Health Care
Group (MHCG), one of the world’s leading providers of
single-use surgical and wound care products and services to the
healthcare sector. MHCG was created from the successful integration
of 3 companies (Regent, Medlock and Mölnlycke) and was
acquired by Investor AB in March 2007 for approximately
€2.85bn. Previous to this John was involved with several
companies including AIM listed Purewafer plc and has held a number
of senior finance
positions in industry, including Ellis & Everard plc andWhessoe
plc
About Tissue Regenix Ltd
Tissue Regenix Limited was formed in May 2006. The underpinning science was developed over the last decade by Professors John Fisher and Eileen Ingham as a result of their research and expertise in biocompatibility, immunocompatibility and functional tissue re-engineering.
Tissue Regenix products, which are produced from animal tissues, have an acellular architectural structure that is comparable to human tissue, and are therefore not perceived as foreign bodies by the host tissue. This lack of rejection allows the Tissue Regenix products to work by supporting fibroblast and smooth muscle cell infiltration, reendothelialisation and revascularisation, so that it gradually becomes incorporated into the surrounding tissue, repairing, replacing or providing strength and support to the tissue defect.
